1 week Ago By ABMN Staff
StockNews.com assumed coverage on shares of Moleculin Biotech ( NASDAQ:MBRX – Free Report ) in a research note issued to investors on Monday morning. The brokerage issued a sell rating on the stock.
Separately, Maxim Group lowered their target price on shares of Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, November 12th.
Get Our Latest Analysis on MBRX Moleculin Biotech Stock Up 3.6 % Institutional Investors Weigh In On Moleculin Biotech An institutional investor recently raised its position in Moleculin Biotech stock. Armistice Capital LLC lifted its holdings in Moleculin Biotech, Inc.
( NASDAQ:MBRX – Free Report ) by 5.1% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 156,000 shares of the company’s stock after acquiring an additional 7,505 shares during the period.
Armistice Capital LLC owned 6.75% of Moleculin Biotech worth $549,000 at the end of the most recent reporting period. 15.
52% of the stock is owned by institutional investors. Moleculin Biotech Company Profile ( Get Free Report ) Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Featured Stories Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter ..
